Nevro Past Earnings Performance

Past criteria checks 0/6

Nevro has been growing earnings at an average annual rate of 9.2%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 2.2% per year.

Key information

9.2%

Earnings growth rate

12.8%

EPS growth rate

Medical Equipment Industry Growth	8.9%
Revenue growth rate	2.2%
Return on equity	-31.5%
Net Margin	-21.7%
Next Earnings Update	07 May 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Nevro makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:NVRO Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	425	-92	335	54
30 Sep 23	423	-102	335	56
30 Jun 23	419	3	332	56
31 Mar 23	415	2	329	55
31 Dec 22	406	3	322	53
30 Sep 22	395	-8	324	52
30 Jun 22	388	-140	325	49
31 Mar 22	386	-136	315	49
31 Dec 21	387	-131	309	48
30 Sep 21	394	-108	294	47
30 Jun 21	409	-68	283	46
31 Mar 21	363	-88	269	45
31 Dec 20	362	-83	267	46
30 Sep 20	367	-90	276	51
30 Jun 20	358	-98	280	53
31 Mar 20	396	-84	296	57
31 Dec 19	390	-104	306	59
30 Sep 19	384	-100	301	56
30 Jun 19	379	-93	292	55
31 Mar 19	382	-76	281	52
31 Dec 18	387	-49	267	48
30 Sep 18	377	-44	239	45
30 Jun 18	364	-39	228	42
31 Mar 18	346	-40	218	40
31 Dec 17	327	-37	220	38
30 Sep 17	299	-42	202	39
30 Jun 17	278	-40	184	37
31 Mar 17	255	-37	165	36
31 Dec 16	229	-32	142	34
30 Sep 16	191	-36	126	28
30 Jun 16	146	-52	112	26
31 Mar 16	102	-63	98	23
31 Dec 15	70	-67	82	21
30 Sep 15	46	-62	64	20
30 Jun 15	39	-50	49	20
31 Mar 15	36	-38	37	20
31 Dec 14	33	-31	30	20
30 Sep 14	29	-29	26	20
30 Jun 14	27	-26	24	19
31 Mar 14	25	-26	21	19
31 Dec 13	24	-26	19	20

Quality Earnings: NVRO is currently unprofitable.

Growing Profit Margin: NVRO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NVRO is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare NVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).

Return on Equity

High ROE: NVRO has a negative Return on Equity (-31.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Nevro Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

Recent updates

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

Price target decreased to US$69.50

General Counsel recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022

Nevro Corp., Annual General Meeting, May 26, 2022

Revenue & Expenses Breakdown
Beta